What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to report Amgen's unaudited financial results for the first quarter ended March 31, 2023. It officially furnishes the company's earnings press release, which contains detailed financial information.

Why does Amgen present non-GAAP financial measures?

Amgen presents non-GAAP financial measures to provide investors with additional information that enhances their understanding of the company's financial performance and future prospects. These measures are intended to offer a clearer view of ongoing business activities by excluding certain expenses such as acquisition-related charges and restructuring costs, which can fluctuate and may obscure underlying operational trends.

What specific non-GAAP financial measures does Amgen report?

Amgen reports several non-GAAP measures including non-GAAP earnings per share, non-GAAP operating income, non-GAAP operating margin, non-GAAP tax rate, non-GAAP net income, and others. They also report Free Cash Flow (FCF) and total revenues and product sales adjusted for foreign exchange impact.

Are the non-GAAP measures a substitute for GAAP measures?

No, Amgen explicitly states that its non-GAAP financial measures are supplementary and not a substitute for, or superior to, measures prepared in accordance with GAAP. Investors should always consider both GAAP and non-GAAP results for a comprehensive view.

AMGN 8-K: Earnings & Results

Summary

Amgen Inc. (AMGN) filed an 8-K on April 27, 2023, to report its First Quarter 2023 financial results. The filing primarily serves to furnish the company's earnings press release, which details both GAAP and non-GAAP financial measures. Investors should note that Amgen emphasizes its non-GAAP results to provide a clearer view of ongoing business performance, excluding items like acquisition-related expenses, restructuring costs, and certain investment and debt-related charges. The company utilizes these non-GAAP measures, alongside Free Cash Flow (FCF) and foreign exchange-adjusted revenue, to enhance understanding of operational performance and liquidity. While these adjustments aim to present a more consistent view of core operations, investors are reminded that these are supplementary and not a replacement for GAAP-based reporting. The details of these adjustments, including specific exclusions and reconciliations, are available in the furnished press release.

Key Highlights

1Amgen Inc. filed an 8-K on April 27, 2023, reporting its Q1 2023 financial results.
2The filing includes Amgen's earnings press release, detailing both GAAP and non-GAAP financial performance.
3The company provides non-GAAP earnings per share, operating income, and net income to offer a view of ongoing business performance.
4Key exclusions from non-GAAP measures include acquisition-related expenses and restructuring costs.
5Amgen also reports Free Cash Flow (FCF) as a key liquidity metric.
6Foreign exchange impact on product sales is adjusted to provide clarity on underlying sales trends.
7The provided information is furnished and not deemed 'filed' under Section 18 of the Securities Exchange Act.

AMGEN INC 8-K Report, Financial Results (Apr 27, 2023)

Summary

Key Highlights

Frequently Asked Questions